( April 27, 2026, 7:17 AM EDT) -- WASHINGTON, D.C. — The manufacturers of Dupixent
XE "Dupixent" , a prescription medication used for the treatment of asthma and inflammatory skin conditions, and individuals in cases across the country that allege that the drug causes cutaneous T-cell lymphoma (CTCL), a rare type of cancer that affects white blood cells called T cells or T lymphocytes, will be able to present oral arguments on May 28 before the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) on which federal court the cases should be centralized....